SELLAS Life Sciences posts $10.1M Q3 loss as pivotal leukemia trial results approach

SELLAS’ financial loss underscores the high stakes of its leukemia trials, potentially impacting future funding and strategic directions.

The post SELLAS Life Sciences posts $10.1M Q3 loss as pivotal leukemia trial results approach appeared first on Crypto Briefing.